Skip to main content
. 2014 Mar 6;7:387–393. doi: 10.2147/OTT.S58870

Figure 3.

Figure 3

Comparison of progression-free survival between patients with and without a T790M epidermal growth factor receptor (EGFR) mutation prior to first-line treatment with an EGFR tyrosine-kinase inhibitor.

Note: Weights are from random-effects analysis.

Abbreviations: CI, confidence interval; HR, hazard ratio.